ESR1 and breast carcinoma: To inhibit the progression of breast cancer, the representative estrogen-dependent disease, an antagonist for estrogen receptor (ER) and/or inhibitors of aromatase, the enzyme involved in estrogen synthesis, have been widely used [7, 8].